Darsana Capital Partners’s NovoCure NVCR Stock Holding History

Darsana Capital Partners’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-258,937	Closed	-$19.4M	–	13
2021 Q4	$19.4M	Sell	258,937 -441,063	-63%	-$44.3M	0.9%	11
2021 Q3	$81.3M	Hold	700,000	–	–	2.68%	14
2021 Q2	$155M	Buy	700,000 +200,000	+40%	+$38.9M	4.42%	12
2021 Q1	$66.1M	Sell	500,000 -250,000	-33%	-$39.5M	1.85%	17
2020 Q4	$130M	Sell	750,000 -575,000	-43%	-$78.7M	3.66%	13
2020 Q3	$147M	Sell	1,325,000 -375,000	-22%	-$30M	7.5%	7
2020 Q2	$101M	Buy	1,700,000 +350,000	+26%	+$23M	5.98%	9
2020 Q1	$90.9M	Hold	1,350,000	–	–	4.3%	9
2019 Q4	$114M	Buy	1,350,000 +350,000	+35%	+$28.3M	3.88%	11
2019 Q3	$74.8M	Sell	1,000,000 -500,000	-33%	-$40M	2.77%	12
2019 Q2	$94.8M	Sell	1,500,000 -250,000	-14%	-$12.7M	3.08%	13
2019 Q1	$84.3M	Sell	1,750,000 -400,000	-19%	-$19.3M	3.16%	11
2018 Q4	$72M	Buy	2,150,000 +1,325,089	+161%	+$48.5M	3.01%	11
2018 Q3	$43.2M	Buy	+824,911	New	+$32.8M	1.36%	15

Other funds holding NVCR

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Darsana Capital Partners's NVCR Position: Q1 2022 in Review

Darsana Capital Partners sold out of NovoCure (NVCR) in Q1 2022, closing a stake of 258,937 shares — an estimated $19.4M sold.

Darsana Capital Partners first reported a position in NVCR in Q3 2018 and held it in 14 quarters. The position peaked at $155M in Q2 2021. 308 funds tracked by Wall St. Rank hold NVCR as of Q1 2022.

Darsana Capital Partners reported no remaining NovoCure position as of Q1 2022 after selling out during the quarter.
Darsana Capital Partners sold 258,937 NovoCure shares in Q1 2022, an estimated $19.4M.
Darsana Capital Partners first reported a position in NovoCure in Q3 2018 and held it in 14 quarters.
Darsana Capital Partners's NovoCure position peaked at $155M in Q2 2021.
308 funds tracked by Wall St. Rank held NovoCure as of Q1 2022.

Based on Darsana Capital Partners's 13F filing for Q1 2022, filed 16 May 2022.